HK1016877A1 - Bioactivated diagnostic imaging contrast agents. - Google Patents

Bioactivated diagnostic imaging contrast agents.

Info

Publication number
HK1016877A1
HK1016877A1 HK99101864A HK99101864A HK1016877A1 HK 1016877 A1 HK1016877 A1 HK 1016877A1 HK 99101864 A HK99101864 A HK 99101864A HK 99101864 A HK99101864 A HK 99101864A HK 1016877 A1 HK1016877 A1 HK 1016877A1
Authority
HK
Hong Kong
Prior art keywords
agents
bioactivated
contrast agents
diagnostic imaging
imaging contrast
Prior art date
Application number
HK99101864A
Other languages
English (en)
Inventor
Randall B Lauffer
Thomas J Mcmurry
Stephen O Dunham
Daniel M Scott
David J Parmelee
Stephane Dumas
Original Assignee
Epix Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Medical Inc filed Critical Epix Medical Inc
Publication of HK1016877A1 publication Critical patent/HK1016877A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK99101864A 1996-04-01 1999-04-27 Bioactivated diagnostic imaging contrast agents. HK1016877A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1444896P 1996-04-01 1996-04-01
PCT/US1997/004804 WO1997036619A2 (en) 1996-04-01 1997-03-25 Bioactivated diagnostic imaging contrast agents

Publications (1)

Publication Number Publication Date
HK1016877A1 true HK1016877A1 (en) 1999-11-12

Family

ID=21765541

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99101864A HK1016877A1 (en) 1996-04-01 1999-04-27 Bioactivated diagnostic imaging contrast agents.

Country Status (19)

Country Link
US (3) US6709646B2 (ko)
EP (1) EP0907379B1 (ko)
JP (2) JP2000507577A (ko)
KR (1) KR20060025233A (ko)
CN (1) CN1108824C (ko)
AT (1) ATE268187T1 (ko)
AU (1) AU726914B2 (ko)
BR (1) BR9708470A (ko)
CA (1) CA2247620A1 (ko)
DE (1) DE69729380T2 (ko)
DK (1) DK0907379T3 (ko)
ES (1) ES2217408T3 (ko)
HK (1) HK1016877A1 (ko)
IL (1) IL125895A (ko)
IS (1) IS2059B (ko)
NO (1) NO319674B1 (ko)
NZ (1) NZ331629A (ko)
PT (1) PT907379E (ko)
WO (1) WO1997036619A2 (ko)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713045B1 (en) 1995-06-02 2004-03-30 Research Corporation Technologies, Inc. Targeted magnetic resonance imaging agents for the detection of physiological processes
US6770261B2 (en) 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US5900228A (en) 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
US6675035B1 (en) * 1997-06-20 2004-01-06 Imaging Diagnostic Systems, Inc. Phantom for optical and magnetic resonance imaging quality control
DE69819925T2 (de) * 1997-10-02 2004-09-02 Epix Medical, Inc., Cambridge Kontrastverstärktes Diagnosebildererzeugungsverfahren zur Überwachung von therapeutischen Eingriffen
AU750686B2 (en) * 1997-10-27 2002-07-25 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the delivery of therapeutic agents
US6713046B1 (en) 1997-10-27 2004-03-30 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
WO1999025389A2 (en) * 1997-11-17 1999-05-27 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
IT1297034B1 (it) * 1997-12-30 1999-08-03 Bracco Spa Acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico
IT1297035B1 (it) * 1997-12-30 1999-08-03 Bracco Spa Derivati dell'acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico
US6167297A (en) 1999-05-05 2000-12-26 Benaron; David A. Detecting, localizing, and targeting internal sites in vivo using optical contrast agents
US6230586B1 (en) * 1999-05-21 2001-05-15 Chung-Hsi Chang Electric drive device for a bicycle
PL353336A1 (en) 1999-07-29 2003-11-17 Epix Medical, Inc. Targeting multimeric imaging agents through multilocus binding
JP2003520255A (ja) * 2000-01-22 2003-07-02 エピックス メディカル， インコーポレイテッド 酵素的な切断によって生理活性化される造影剤プロドラッグを使用した磁気共鳴画像法
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US20040146463A1 (en) * 2000-05-04 2004-07-29 Meade Thomas J. Functional MRI agents for cancer imaging
EP1278553A2 (en) * 2000-05-04 2003-01-29 Research Corporation Technologies, Inc Magnetic resonance imaging agents for the delivery of therapeutic agents
US6673333B1 (en) * 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
EP1283728A2 (en) * 2000-05-23 2003-02-19 Amersham Health AS Contrast agents
US6748259B1 (en) 2000-06-15 2004-06-08 Spectros Corporation Optical imaging of induced signals in vivo under ambient light conditions
US6656450B2 (en) 2000-07-17 2003-12-02 California Institute Of Technology, Inc. Macrocyclic magnetic resonance imaging contrast agents
US7029655B2 (en) 2000-10-04 2006-04-18 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
US20030004236A1 (en) * 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
US20020197648A1 (en) * 2001-05-02 2002-12-26 Silva Robin M. High throughput screening methods using magnetic resonance imaging agents
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
ES2506142T3 (es) 2002-03-01 2014-10-13 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
CA2513044A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US20030198597A1 (en) * 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
DE60322076D1 (de) * 2002-07-22 2008-08-21 Bracco Imaging Spa Zellmarkierungsverfahren mit paramagnetischen komplexen für mrt-anwendungen
US20050163821A1 (en) * 2002-08-02 2005-07-28 Hsing-Wen Sung Drug-eluting Biodegradable Stent and Delivery Means
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
PT2949658T (pt) 2003-03-03 2018-10-18 Bracco Suisse Sa Péptidos que ligam especificamente o recetor de hgf (cmet) e utilizações dos mesmos
EP2338525A3 (en) * 2003-07-09 2011-08-03 California Pacific Medical Center Remote detection of substance delivery to cells
US20050106100A1 (en) * 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
US20050124008A1 (en) * 2003-12-05 2005-06-09 Kauvar Lawrence M. Homogeneous competition assays
NO20035683D0 (no) * 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av prostatakreft
FR2868320B1 (fr) * 2004-03-31 2007-11-02 Centre Nat Rech Scient Cnrse Agent de contraste pour l'imagerie par resonance magnetique
US8728463B2 (en) * 2005-03-11 2014-05-20 Wake Forest University Health Science Production of tissue engineered digits and limbs
US20060204445A1 (en) * 2005-03-11 2006-09-14 Anthony Atala Cell scaffold matrices with image contrast agents
US7531503B2 (en) * 2005-03-11 2009-05-12 Wake Forest University Health Sciences Cell scaffold matrices with incorporated therapeutic agents
US20060204539A1 (en) 2005-03-11 2006-09-14 Anthony Atala Electrospun cell matrices
EP1863547B1 (en) * 2005-03-11 2016-05-11 Wake Forest University Health Sciences Tissue engineered blood vessels
WO2006099334A2 (en) * 2005-03-11 2006-09-21 Wake Forest University Health Sciences Production of tissue engineered heart valves
EP1896086A1 (en) * 2005-06-30 2008-03-12 Bristol-Myers Squibb Pharma Company Hydrazide conjugates as imaging agents
EP1745739A3 (en) 2005-07-14 2009-04-22 Bundesrepublik Deutschland, vertr. d.d. Bundes- ministerium f. Wirtschaft- und Technologie, dieses vertr. d.d. Präs. d. Phys.-Techn. Bundesanstalt Optical imaging of rheumatoid arthritis
JP5377965B2 (ja) * 2005-09-09 2013-12-25 ジョージア ステート ユニバーシティ リサーチ ファウンデーション、インコーポレイテッド 標的化された造影剤および造影剤を標的化するための方法
WO2007084264A2 (en) * 2005-12-29 2007-07-26 Epix Pharmaceuticals, Inc. Methods for myocardial imaging
WO2009026177A1 (en) 2007-08-17 2009-02-26 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
JPWO2009054327A1 (ja) * 2007-10-22 2011-03-03 財団法人大阪産業振興機構 Ｍｒｉ用プローブ
WO2010107832A1 (en) 2009-03-17 2010-09-23 Bracco Imaging Spa Lhrh-ii peptide analogs
MX2011009716A (es) 2009-03-19 2011-10-17 Wyeth Llc Metodos para la preparacion de acido [2-(8,9-dioxo)-2,6-diazabicic lo[5.2.0]non-1(7)-en-2-il)etil]fosfonico y precursores de este.
WO2010121133A2 (en) 2009-04-17 2010-10-21 The General Hospital Corporation Multimodal imaging of fibrin
JP2011026294A (ja) 2009-06-26 2011-02-10 Canon Inc 化合物
WO2011035140A1 (en) 2009-09-18 2011-03-24 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of contrast moieties to the lungs
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
CN102188722A (zh) * 2010-03-18 2011-09-21 中国科学院福建物质结构研究所 一种含二价铁的磁共振成像造影剂
US8192429B2 (en) 2010-06-29 2012-06-05 Theravant, Inc. Abnormality eradication through resonance
WO2013131994A2 (en) * 2012-03-08 2013-09-12 Thommen Medical Ag Coating for the diagnosis of inflammatory tissues in dental applications
KR102057132B1 (ko) * 2012-03-08 2019-12-18 토멘 메디칼 아게 염증성 조직을 진단하기 위한 치과적 용도의 츄잉검
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
CN105636924B (zh) 2013-10-18 2018-08-07 德国癌症研究中心 前列腺特异性膜抗原(psma)的标记的抑制剂，它们作为显影剂和用于治疗前列腺癌的药剂的用途
US10092679B2 (en) 2013-10-18 2018-10-09 Wake Forest University Health Sciences Laminous vascular constructs combining cell sheet engineering and electrospinning technologies
WO2015171543A1 (en) 2014-05-05 2015-11-12 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
US10471162B2 (en) 2014-06-20 2019-11-12 The General Hospital Corporation Collagen targeted imaging probes
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
EP3270951B1 (en) 2015-03-16 2020-09-09 California Institute of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
CN115112898A (zh) 2015-07-15 2022-09-27 加州理工学院 Il-17f-特异性捕获剂、组合物以及使用和制造的方法
CN109476721B (zh) 2016-04-04 2022-06-28 英蒂分子公司 Cd8-特异性捕获剂、组合物及使用和制备方法
EP3519425B1 (en) 2016-09-29 2024-02-28 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
WO2018085375A1 (en) 2016-11-01 2018-05-11 Ohio State Innovation Foundation Methods for the iodination of biomolecules
SG11201908911QA (en) * 2017-04-27 2019-11-28 Univ California Modified mri contrast agents and uses thereof
US11719705B2 (en) 2017-06-15 2023-08-08 Indi Molecular, Inc. IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making
US12036234B2 (en) 2017-10-11 2024-07-16 Northwestern University Heparin conjugated to collagen-binding peptides for targeting to biological and synthetic tissues
CN108314695B (zh) * 2018-01-04 2020-06-16 南京邮电大学 一种异种双核金属配合物的制备及应用
WO2020093055A2 (en) 2018-11-02 2020-05-07 Indi Molecular, Inc. Peptide libraries with non-canonical amino acids
WO2020097531A1 (en) 2018-11-08 2020-05-14 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
WO2020186091A1 (en) 2019-03-12 2020-09-17 Indi Molecular, Inc. Cross-linked epitopes and methods of use thereof
EP3972646A4 (en) 2019-05-20 2023-06-14 Ohio State Innovation Foundation APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USE THEREOF
US20200371101A1 (en) 2019-05-20 2020-11-26 Indi Molecular, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (ido1)
US11414460B2 (en) 2019-07-19 2022-08-16 Institute For Systems Biology KRAS-specific capture agents, compositions, and methods of making and using
CN112891566A (zh) * 2019-12-04 2021-06-04 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 一种纳米材料及其制备方法和包含其的造影剂
BR112022022045A2 (pt) 2020-04-30 2023-01-10 Sairopa B V Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd103 humano, um ou mais ácidos nucleicos, sistema de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou fragmento de ligação ao antígeno, para detectar a presença de cd103 em uma amostra biológica, para tratar ou prevenir uma condição mediada por sinalização de cd103 em um indivíduo em necessidade, para inibir a sinalização de cd103 em uma célula, para inibir a ligação de cd103 à e-caderina presente em uma célula, para retirar as células que expressam cd103 em um indivíduo, para tratar ou prevenir uma doença e agente de imageamento
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880008A (en) 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US4899755A (en) 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
WO1988002635A1 (en) * 1986-10-17 1988-04-21 Cytogen Corporation Method for preparation of protein-chelator-metal ion compositions suitable for injection
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
US5171563A (en) 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
US5094848A (en) * 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
JPH05503072A (ja) * 1989-08-28 1993-05-27 ザ・ゼネラル・ホスピタル・コーポレーション 診断用ｎｍｒ映像化の為のヒドロキシ―アリール金属キレート
USH1312H (en) * 1992-05-28 1994-05-03 Cytogen Corporation Method for the preparation of gyk-dtpa
EP0664713B1 (en) * 1992-10-14 2000-01-19 Nycomed Imaging As Therapeutic and diagnostic imaging compositions and methods
EP0731797B1 (en) * 1993-12-03 1999-09-08 BRACCO S.p.A. Paramagnetic chelates for nuclear magnetic resonance diagnosis
DE4341724A1 (de) 1993-12-03 1995-06-08 Schering Ag Halogenaryl-substituierte Metallkomplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik, sowie Verfahren zur Herstellung der Komplexe und Mittel
TW319763B (ko) * 1995-02-01 1997-11-11 Epix Medical Inc
DE19507822B4 (de) * 1995-02-21 2006-07-20 Schering Ag Substituierte DTPA-Monoamide der zentralen Carbonsäure und deren Metallkomplexe, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik und Therapie sowie Verfahren zur Herstellung der Komplexe und Mittel
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5707605A (en) 1995-06-02 1998-01-13 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents

Also Published As

Publication number Publication date
DK0907379T3 (da) 2004-08-16
CA2247620A1 (en) 1997-10-09
CN1108824C (zh) 2003-05-21
KR20060025233A (ko) 2006-03-20
US6709646B2 (en) 2004-03-23
US20040156785A1 (en) 2004-08-12
NO984543L (no) 1998-11-26
WO1997036619A2 (en) 1997-10-09
DE69729380D1 (de) 2004-07-08
DE69729380T2 (de) 2005-07-14
NO984543D0 (no) 1998-09-29
NO319674B1 (no) 2005-09-05
NZ331629A (en) 2000-04-28
AU726914B2 (en) 2000-11-23
ES2217408T3 (es) 2004-11-01
US20060275216A1 (en) 2006-12-07
IS2059B (is) 2005-10-14
IS4833A (is) 1998-08-26
CN1215341A (zh) 1999-04-28
PT907379E (pt) 2004-09-30
WO1997036619A3 (en) 1998-01-29
EP0907379B1 (en) 2004-06-02
AU2544897A (en) 1997-10-22
JP2000507577A (ja) 2000-06-20
IL125895A (en) 2001-09-13
IL125895A0 (en) 1999-04-11
JP2004210796A (ja) 2004-07-29
US20020034476A1 (en) 2002-03-21
ATE268187T1 (de) 2004-06-15
BR9708470A (pt) 1999-04-13
US7147837B2 (en) 2006-12-12
EP0907379A2 (en) 1999-04-14

Similar Documents

Publication Publication Date Title
HK1016877A1 (en) Bioactivated diagnostic imaging contrast agents.
NO20002380D0 (no) Forbindelser for før-døden diagnose av Alzheimers sykdom og in vivo billeddannelse, samt forhindring av amyloid deponering
EP0994352A3 (en) Contrast agent enhanced magnetic resonance imaging of myocardial tissue
CA2268324A1 (en) Administrable compositions and methods for magnetic resonance imaging
YU6502A (sh) Usmeravanje multimernih agenasa za dobijanje kontrasta pri dijagnostičkom snimanju putem multilokusnog vezivanja
CA2222974A1 (en) Magnetic resonance imaging agents for the detection of physiological agents
AU4918896A (en) Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
AU5672194A (en) Apparatus for diagnostic imaging
WO2001082976A3 (en) Functional mri agents for cancer imaging
WO2002051301A3 (en) Fullerene (c60)-based x-ray contrast agent for diagnostic imaging
WO1999025389A3 (en) Magnetic resonance imaging agents for the detection of physiological agents
HUP9900426A3 (en) Amyloid binding azoderivatives, preparation thereof and use of these compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
WO2003088823A3 (en) Novel macrocyclic activatible magnetic resonance imaging contrast agents
GB0130305D0 (en) Compounds for imaging alzheimers disease
IL121084A0 (en) Compositions and methods for diagnosis of tumors by X-ray imaging
AU4546996A (en) Liposome suspensions as blood pool imaging contrast agents
EP1048302A3 (en) Radiotracers for in vivo study of acetylcholinesterase and Alzheimer's disease
EP0948361A4 (en) MAGNETIC RESONANCE BLOOD POOL IMAGING AGENTS
AU5187696A (en) Nanoparticulate diagnostic triiodo benzoate derivatives as x-ray contrast agents for blood pool and lymphatic system imaging
UA41932C2 (uk) Засіб для ямр-томографії
IL133426A0 (en) Compositions and methods for diagnosis of tumors by x-ray imaging
UA29125A (uk) Спосіб діагностики розсіяного склерозу

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080325